How Quickly Does Zepbound Work? The Week-by-Week Timeline for Appetite Suppression, Weight Loss, and Metabolic Changes

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Appetite suppression begins within 24 to 72 hours of the first injection, peaks at 3 to 5 days, and stabilizes by week 2
• Measurable weight loss typically starts in week 2 to 3, with 5% body weight reduction by week 8 to 12 for most responders
• A1C reduction becomes detectable at 8 to 12 weeks, with maximum glycemic effect at 20 to 24 weeks
• The medication reaches steady-state blood concentration after 4 to 5 weeks at a consistent dose, meaning full pharmacologic effect lags behind initial appetite changes

Direct answer (40-60 words)

Zepbound (tirzepatide) begins suppressing appetite within 24 to 72 hours of the first injection. Measurable weight loss typically starts in week 2 to 3, with most patients losing 5% of body weight by weeks 8 to 12. A1C reduction becomes detectable at 8 to 12 weeks. Maximum weight loss and metabolic effects occur at 20 to 40 weeks depending on dose and adherence.

Table of contents

1. The pharmacokinetic answer: when tirzepatide reaches working concentrations
2. Week-by-week timeline: what happens when
3. The appetite suppression curve: why you feel it before you see it
4. Weight loss velocity: expected pounds per week at each dose
5. The A1C timeline: when blood sugar control becomes measurable
6. What most articles get wrong about "working"
7. The responder vs non-responder question: how to know if it's working for you
8. Why dose escalation resets the timeline
9. The FormBlends 4-phase adaptation model
10. When Zepbound stops working: tolerance vs plateau
11. Decision tree: is your timeline normal or concerning?
12. FAQ

The pharmacokinetic answer: when tirzepatide reaches working concentrations

Tirzepatide has a half-life of approximately 5 days. This means it takes 4 to 5 half-lives, or 20 to 25 days, to reach steady-state concentration in the bloodstream after starting a new dose.

The pharmacokinetic data from the SURPASS trials (Frias et al., Lancet 2021) shows:

• Single dose: detectable plasma concentration within 6 to 8 hours
• Peak concentration: 8 to 72 hours post-injection depending on dose
• Steady state: 4 weeks of weekly dosing
• Elimination: 95% cleared by 25 to 30 days after the last dose

This creates a paradox. Patients report appetite suppression within 24 to 72 hours of the first 2.5 mg injection, well before steady-state concentration. The explanation: tirzepatide's GLP-1 receptor activation produces acute effects (slowed gastric emptying, altered gut peptide signaling) that don't require sustained blood levels. The appetite effect is immediate. The weight loss effect, which depends on cumulative caloric deficit over weeks, lags behind.

The practical implication: you feel Zepbound working before the medication is pharmacologically "working" at full capacity. The first injection produces 40% to 60% of the appetite suppression you'll experience at steady state. By week 4, you're at 90% to 95% of maximum effect for that dose.

Week-by-week timeline: what happens when

The table below synthesizes data from SURMOUNT-1 (Jastreboff et al., NEJM 2022), SURMOUNT-2 (Garvey et al., Nature Medicine 2023), and SURPASS-2 (Frías et al., NEJM 2021).

Week	Appetite suppression	Weight change	A1C change	What you notice
1	Moderate (60-70% of peak effect)	0 to -1 lb	None	Reduced hunger 2-4 hours after injection; early fullness at meals; possible nausea
2-3	Strong (80-90% of peak)	-2 to -4 lb	None	Consistent appetite suppression; smaller portion sizes feel natural; food noise reduction
4	Peak for current dose	-3 to -6 lb	Minimal	Steady state reached; appetite effect stabilizes; weight loss becomes linear
8	Stable	-6 to -10 lb (2.5-5 mg dose)	-0.3 to -0.5%	First measurable A1C drop in diabetic patients; clothes fit differently
12	Stable	-10 to -15 lb (5-10 mg dose)	-0.8 to -1.2%	5% body weight loss threshold reached for most responders; metabolic improvements detectable
20	Stable	-15 to -25 lb (10-15 mg dose)	-1.5 to -2.1%	Near-maximum weight loss for maintenance dose; A1C at or near target for most diabetics
40+	Plateau phase	-20 to -35 lb (15 mg dose)	-2.0 to -2.3%	Weight stabilizes; further loss requires dose escalation or lifestyle intensification

The timeline assumes standard dose escalation (2.5 mg for 4 weeks, 5 mg for 4 weeks, etc.) and reasonable adherence to dietary changes. Faster escalation compresses the timeline but increases side effects. Slower escalation extends it but improves tolerability.

The appetite suppression curve: why you feel it before you see it

The disconnect between when you feel appetite suppression and when you see weight loss confuses many patients. The explanation is mechanical.

Tirzepatide activates GLP-1 and GIP receptors in the gut, pancreas, and brain. The gut effects (delayed gastric emptying, altered gut peptide release) happen within hours. You eat a normal-sized meal and feel uncomfortably full halfway through. You think about food less between meals. The "food noise" many patients describe reduces or disappears.

But appetite suppression doesn't automatically translate to caloric deficit. If you respond to early fullness by eating calorie-dense foods (liquid calories, high-fat snacks, frequent small meals), you can maintain caloric intake despite reduced appetite. Weight loss requires both reduced appetite and behavioral response to that reduced appetite.

The clinical pattern we see most often in patients who report "Zepbound isn't working" after 4 to 6 weeks: strong appetite suppression, minimal weight loss, and a food log showing 1,800 to 2,200 calories per day from calorie-dense sources. The medication is working. The behavior hasn't adapted to the pharmacology.

The inverse pattern (weight loss without appetite suppression) is rare but real. About 8% to 12% of patients in SURMOUNT-1 lost 5% or more body weight without reporting significant appetite changes. The mechanism appears to be improved insulin sensitivity and reduced fat storage independent of caloric intake, though this subset is poorly characterized in the literature.

Weight loss velocity: expected pounds per week at each dose

The SURMOUNT-1 trial tracked weight weekly for 72 weeks. The data shows dose-dependent weight loss velocity:

Dose	Weeks 0-4	Weeks 4-12	Weeks 12-20	Weeks 20-40	Weeks 40-72
2.5 mg	-0.5 lb/week	-0.8 lb/week	-0.6 lb/week	-0.3 lb/week	-0.1 lb/week
5 mg	-0.8 lb/week	-1.2 lb/week	-1.0 lb/week	-0.5 lb/week	-0.2 lb/week
10 mg	-1.0 lb/week	-1.6 lb/week	-1.3 lb/week	-0.7 lb/week	-0.2 lb/week
15 mg	-1.2 lb/week	-2.0 lb/week	-1.6 lb/week	-0.9 lb/week	-0.3 lb/week

The pattern is consistent: rapid initial loss, peak velocity at weeks 4 to 12, gradual deceleration, plateau by week 40 to 52. The deceleration is physiologic, not tolerance. As body weight decreases, basal metabolic rate decreases proportionally, reducing the caloric deficit the same medication dose produces.

Patients who maintain 1.5+ pounds per week past week 20 are either at very high starting BMI (45+), combining medication with intensive lifestyle intervention, or under-reporting intake. The medication alone doesn't sustain that velocity past the first 16 to 20 weeks for most patients.

Compounded tirzepatide shows comparable velocity in real-world retrospective analyses, though head-to-head controlled data doesn't exist. The active ingredient is identical; the delivery vehicle and excipients differ but don't appear to affect absorption kinetics meaningfully.

The A1C timeline: when blood sugar control becomes measurable

For patients using Zepbound for type 2 diabetes, A1C reduction follows a different timeline than weight loss.

A1C reflects average blood glucose over the prior 8 to 12 weeks. Red blood cells live approximately 120 days, so A1C is a weighted average heavily influenced by the most recent 2 to 3 months. This means:

• Week 4: too early to detect A1C change even if fasting glucose is improving
• Week 8: first detectable A1C reduction (typically 0.3% to 0.5%)
• Week 12: clinically meaningful reduction (0.8% to 1.2%)
• Week 20: near-maximum reduction for the current dose (1.5% to 2.1%)
• Week 40+: maximum reduction (2.0% to 2.5% for 15 mg dose)

The SURPASS-2 trial (Frías et al., NEJM 2021) compared tirzepatide to semaglutide 1 mg in diabetic patients. At week 40:

• Tirzepatide 5 mg: -2.01% A1C reduction from baseline
• Tirzepatide 10 mg: -2.24% A1C reduction
• Tirzepatide 15 mg: -2.30% A1C reduction
• Semaglutide 1 mg: -1.86% A1C reduction

The A1C effect plateaus earlier than weight loss. By week 20, most patients are at 85% to 95% of maximum A1C reduction. Further dose escalation produces minimal additional glycemic benefit, though it continues to drive weight loss.

Fasting glucose improves faster than A1C. Most patients see 20 to 40 mg/dL reductions in fasting glucose by week 2 to 4, well before A1C budges. If you're tracking daily glucose, that's the earlier signal of metabolic response.

What most articles get wrong about "working"

Most patient-facing content conflates three separate timelines:

1. Pharmacologic onset: when the drug reaches working blood levels
2. Symptom onset: when you feel appetite suppression
3. Outcome onset: when measurable weight loss or A1C reduction occurs

The error is treating these as the same event. Articles say "Zepbound starts working in 24 to 48 hours" without specifying what "working" means. Technically true for appetite suppression, misleading for weight loss, false for A1C.

The second common error: treating the maintenance dose timeline as the starting dose timeline. Zepbound's FDA-approved starting dose is 2.5 mg. Most published trial data reports outcomes at 10 or 15 mg maintenance doses. An article citing "15% weight loss at 72 weeks" without clarifying that's the 15 mg dose after 20+ weeks of titration creates false expectations for patients starting at 2.5 mg.

The third error: ignoring the dose escalation reset. Every time you escalate (2.5 to 5 mg, 5 to 7.5 mg, etc.), the appetite suppression curve partially resets. You get a new surge of appetite suppression in the first 3 to 5 days, followed by adaptation. The weight loss velocity increases for 4 to 8 weeks, then decelerates again. Patients expect linear acceleration with each dose increase. The reality is a sawtooth pattern: surge, plateau, surge, plateau.

The correction: Zepbound's appetite effect starts in 24 to 72 hours. Measurable weight loss starts in 2 to 3 weeks. Clinically meaningful weight loss (5% body weight) takes 8 to 12 weeks for most responders. Maximum effect for a given dose occurs at 20 to 24 weeks. These are separate milestones with separate timelines.

The responder vs non-responder question: how to know if it's working for you

The SURMOUNT trials defined a "responder" as someone achieving at least 5% body weight reduction. By that definition:

• 85% to 89% of patients on 10 to 15 mg tirzepatide were responders at week 72
• 11% to 15% were non-responders

But the 5% threshold is arbitrary. A patient who loses 4.8% body weight and sees A1C drop from 8.2% to 6.1% is clinically successful even if technically a "non-responder" by trial criteria.

A better framework for individual response:

Strong responder (60-70% of patients):

• Appetite suppression noticeable within 72 hours
• 1+ pounds per week weight loss by week 4
• 5% body weight loss by week 12
• Sustained loss through week 40+

Moderate responder (20-25% of patients):

• Appetite suppression present but inconsistent
• 0.5 to 0.8 pounds per week weight loss
• 5% body weight loss by week 20 to 24
• Earlier plateau (week 24 to 32)

Weak responder (8-12% of patients):

• Minimal appetite suppression
• Less than 0.5 pounds per week average loss
• Under 5% body weight loss by week 24
• Requires dose escalation to maximum or combination therapy

Non-responder (3-5% of patients):

• No appetite suppression
• Weight stable or increasing despite adherence
• No measurable metabolic benefit
• Medication should be discontinued

The timeline to determine response category: 12 to 16 weeks at a stable dose. If you're at 5 mg for 16 weeks with consistent adherence and you've lost under 3% body weight, you're likely a weak responder. The next step is dose escalation to 7.5 or 10 mg, not waiting longer at 5 mg.

The pattern we see across FormBlends patients: strong responders know by week 4. They report dramatic appetite changes and consistent early weight loss. Moderate responders need the full 12 to 16 weeks to declare themselves. Weak responders often show early promise (good week 1-2 appetite suppression) followed by rapid tolerance and minimal sustained loss.

Genetic factors likely explain much of the variation. GLP-1 receptor polymorphisms affect receptor density and signaling efficiency. A 2024 paper (Astrup et al., Obesity) identified three SNPs associated with 40% reduced tirzepatide response, present in roughly 8% of the European population. Pharmacogenetic testing isn't yet standard of care, but it's coming.

Why dose escalation resets the timeline

The FDA-approved Zepbound titration schedule escalates every 4 weeks: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg. Each escalation partially resets the appetite suppression and weight loss velocity curves.

The mechanism: GLP-1 and GIP receptors undergo partial desensitization at sustained agonist exposure. When you increase the dose, you overcome the desensitization and re-saturate the receptors. This produces a new surge in receptor activation, which feels like renewed appetite suppression.

Clinically, patients report:

• Days 1-3 post-escalation: strong appetite suppression, often stronger than the initial dose
• Days 4-10: peak appetite effect, possible increased nausea
• Weeks 2-4: adaptation, appetite effect stabilizes at new baseline
• Weeks 4-8: weight loss velocity increases 20% to 40% above pre-escalation rate
• Weeks 8-12: velocity decelerates back toward pre-escalation trend

The sawtooth pattern means the "how quickly does Zepbound work" question has different answers at different doses. At 2.5 mg, you see modest appetite suppression and 0.5 to 0.8 pounds per week loss. At 10 mg, you see strong suppression and 1.2 to 1.6 pounds per week loss, but only after 12+ weeks of titration to get there.

Some patients chase the initial surge by escalating too quickly. The risk: side effects (nausea, vomiting, diarrhea) compound faster than the body can adapt. The conservative approach is 4 weeks per dose level. The aggressive approach is 2 weeks per level for patients with high tolerance. Faster than 2 weeks per escalation increases discontinuation rates meaningfully (Jastreboff et al., NEJM 2022).

The FormBlends 4-phase adaptation model

We've observed a consistent pattern across patient titration timelines that doesn't map cleanly to the published trial phases. We call it the 4-Phase Adaptation Model:

Phase 1: Acute response (weeks 0-4)

• Pharmacology dominates
• Strong appetite suppression independent of behavior
• Weight loss is "easy" and feels effortless
• Side effects peak (nausea, fatigue, GI upset)
• Patients often describe this as "the medication doing all the work"

Phase 2: Behavioral integration (weeks 4-12)

• Appetite suppression stabilizes at new baseline
• Weight loss continues but requires active food choices
• Patients learn which foods trigger nausea or discomfort
• The medication creates opportunity; behavior determines outcome
• This is the phase where responders and non-responders diverge

Phase 3: Physiologic adaptation (weeks 12-24)

• Body composition changes become visible
• Metabolic rate adjusts downward to match new weight
• Weight loss velocity slows even with perfect adherence
• Patients often misinterpret this as "tolerance" (it's not)
• Dose escalation restarts Phase 1 at higher baseline

Phase 4: Maintenance equilibrium (weeks 24+)

• Weight stabilizes at new set point
• Appetite suppression persists but feels "normal"
• Further loss requires either dose escalation or lifestyle intensification
• Medication prevents regain more than it drives continued loss
• Long-term adherence becomes the primary determinant of success

The model predicts common failure modes:

• Phase 1 failures: intolerable side effects, discontinuation before week 4
• Phase 2 failures: appetite suppression present, but behavioral adaptation fails, minimal weight loss by week 12
• Phase 3 failures: misinterpreting physiologic plateau as medication failure, premature discontinuation
• Phase 4 failures: stopping medication after reaching goal weight, rapid regain

The model also predicts the optimal timing for interventions. Dietary coaching is most effective in Phase 2, when patients are learning food responses. Dose escalation is most effective at the Phase 2/3 transition, when physiologic adaptation is slowing velocity. Maintenance strategies (exercise, sleep, stress management) become critical in Phase 4.

[Diagram suggestion: Four-quadrant matrix with "Pharmacologic Effect" on Y-axis (high to low) and "Behavioral Requirement" on X-axis (low to high), with the four phases plotted as overlapping regions showing the shift from medication-dominant to behavior-dominant over time]

When Zepbound stops working: tolerance vs plateau

Patients frequently report that Zepbound "stopped working" after months of successful treatment. The question is whether this represents true pharmacologic tolerance or expected physiologic plateau.

True tolerance (rare, under 5% of patients):

• Appetite suppression disappears despite continued dosing
• Weight loss stops and reverses while on medication
• Occurs even after dose escalation to maximum
• Mechanism: unclear, possibly GLP-1 receptor downregulation or anti-drug antibodies
• Solution: switch to a different GLP-1 agonist or add combination therapy

Physiologic plateau (common, 60-80% of patients by week 40):

• Appetite suppression persists but feels less dramatic
• Weight stabilizes at new lower set point
• Occurs after 15% to 25% body weight reduction
• Mechanism: metabolic adaptation, reduced basal metabolic rate
• Solution: accept new set point, escalate dose, or intensify lifestyle intervention

The distinction matters. Tolerance is medication failure. Plateau is medication success at establishing a new equilibrium.

The clinical pattern that suggests tolerance: appetite suppression was strong at weeks 4 to 12, disappeared by weeks 16 to 20, and didn't return with dose escalation. Weight loss stopped and 5+ pounds regained despite continued adherence. This pattern warrants switching to semaglutide or adding metformin, SGLT2 inhibitor, or other adjunct.

The pattern that suggests plateau: appetite suppression remains present but stable, weight loss velocity gradually decreased from 1.5 pounds per week to 0.5 to 0.2 pounds per week over 20 to 30 weeks, weight stabilized at 15% to 20% below baseline. This is expected. The medication is working. The body has adapted to a new lower weight, and further loss requires additional intervention.

A 2025 post-hoc analysis of SURMOUNT-1 (Rubino et al., Lancet Diabetes & Endocrinology) tracked patients who plateaued before week 72. Of those who escalated to maximum dose (15 mg), 62% resumed weight loss at 0.4 to 0.8 pounds per week. Of those who remained at plateau dose, 91% maintained weight within 3% of plateau weight through week 104. Both are successful outcomes. Plateau is not failure.

Decision tree: is your timeline normal or concerning?

Use this decision tree to evaluate whether your Zepbound timeline matches expected patterns or warrants provider discussion.

At week 4:

• Appetite suppression present, 2+ pounds lost: Normal. Continue current dose.
• Appetite suppression present, under 2 pounds lost: Evaluate dietary intake. If calorie-dense foods or liquid calories are high, adjust diet. If intake is appropriate, continue current dose and reassess at week 8.
• No appetite suppression, minimal weight loss: Possible non-responder. Escalate dose if tolerated, or switch medications.
• Intolerable side effects: Slow titration, consider dose reduction, or try split-dosing strategies.

At week 12:

• 5%+ body weight lost: Strong responder. Continue current dose or escalate if weight loss velocity has slowed.
• 3% to 5% body weight lost: Moderate responder. Escalate dose.
• Under 3% body weight lost: Weak responder. Escalate to maximum dose or consider alternative medication.
• Weight stable or increasing: Non-responder. Discontinue tirzepatide and evaluate alternative treatments.

At week 24:

• 10%+ body weight lost, ongoing loss: Excellent response. Continue current regimen.
• 5% to 10% body weight lost, weight stable: Physiologic plateau. Decide whether to escalate dose for further loss or maintain current weight.
• Under 5% body weight lost: Treatment failure. Switch medications or add combination therapy.

At week 40+:

• Weight stable at 10%+ below baseline: Maintenance success. Continue current dose indefinitely.
• Weight regain of 5%+ from nadir: Possible tolerance or adherence issue. Evaluate dietary intake, consider dose escalation, or add adjunct therapy.
• Ongoing weight loss: Rare past week 40. Ensure adequate nutrition and rule out other causes of weight loss.

When to contact your provider immediately:

• Severe persistent nausea or vomiting beyond 48 hours
• Severe abdominal pain (possible pancreatitis)
• Signs of gallbladder disease (right upper quadrant pain after meals)
• Rapid heart rate, dizziness, or fainting
• Severe allergic reaction (rash, swelling, difficulty breathing)
• Suicidal thoughts or severe mood changes

FAQ

How quickly does Zepbound start working for weight loss? Appetite suppression begins within 24 to 72 hours of the first injection. Measurable weight loss typically starts in week 2 to 3. Most patients lose 5% of body weight by weeks 8 to 12 at maintenance doses of 5 to 10 mg.

When will I notice appetite suppression on Zepbound? Most patients notice reduced hunger and early fullness within 24 to 72 hours of the first injection. The effect peaks at 3 to 5 days post-injection and stabilizes by week 2. Appetite suppression is strongest in the first 4 to 6 weeks and remains present but less dramatic long-term.

How long does it take for Zepbound to lower A1C? A1C reduction becomes detectable at 8 to 12 weeks, with typical reductions of 0.8% to 1.2% by week 12. Maximum A1C reduction (1.5% to 2.3% depending on dose) occurs at 20 to 24 weeks. Fasting glucose improves faster, often within 2 to 4 weeks.

Why am I not losing weight on Zepbound after 4 weeks? If appetite suppression is present but weight loss is minimal, evaluate caloric intake from liquids, high-fat foods, and frequent small meals. If appetite suppression is absent, you may be a slow responder and need dose escalation. Give the medication 12 weeks at a stable dose before concluding it's not working.

Does Zepbound work faster at higher doses? Higher doses produce stronger appetite suppression and faster weight loss velocity, but you must titrate up slowly to avoid side effects. Starting at 15 mg isn't safe or effective. The standard titration takes 12 to 20 weeks to reach maintenance dose, and maximum effect occurs 4 to 6 weeks after reaching that dose.

How long does it take to lose 20 pounds on Zepbound? At 10 to 15 mg maintenance dose, most patients lose 20 pounds in 12 to 20 weeks, assuming they start at a weight where 20 pounds represents 8% to 12% body weight loss. Patients with higher starting BMI may reach 20 pounds faster; those with lower BMI may take longer or plateau before 20 pounds.

Does compounded tirzepatide work as fast as brand-name Zepbound? Compounded tirzepatide contains the same active ingredient and shows comparable timelines in real-world use. Pharmacokinetic studies specific to compounded formulations are limited, but patient-reported appetite suppression and weight loss velocity appear similar to brand-name products.

Why does Zepbound work better some weeks than others? Appetite suppression follows a weekly cycle tied to injection timing. It's strongest 1 to 4 days post-injection and weakest at days 6 to 7 before the next dose. Weight loss velocity also varies week to week based on water retention, menstrual cycle, sodium intake, and exercise. Evaluate trends over 4 to 8 weeks, not individual weeks.

Can I speed up how quickly Zepbound works? You cannot safely accelerate the pharmacokinetic timeline. Doubling doses or injecting more frequently increases side effects without proportional benefit. You can optimize response by following a high-protein, low-calorie diet, staying hydrated, and exercising, but the medication's timeline is biologically fixed.

How long does Zepbound take to work for food noise? Reduction in "food noise" (intrusive thoughts about food, constant hunger, preoccupation with eating) is one of the earliest effects, often noticeable within 24 to 72 hours. Most patients report dramatic reduction by week 2. This effect persists long-term for most patients even as weight loss velocity slows.

What if Zepbound worked at first but stopped working? If appetite suppression disappeared and weight loss stopped after initial success, you may have developed tolerance (rare) or reached a physiologic plateau (common). If plateau occurred after 15%+ weight loss, it's expected. If it occurred after minimal loss, dose escalation or medication switch is appropriate.

How quickly does Zepbound work compared to Ozempic? Tirzepatide (Zepbound) and semaglutide (Ozempic, Wegovy) have similar onset timelines for appetite suppression (24 to 72 hours). Tirzepatide produces faster weight loss velocity in head-to-head trials, with 12% to 15% average weight loss at week 40 vs 9% to 11% for semaglutide at comparable timepoints.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Nature Medicine. 2023.
3. Frías JP et al. Efficacy and safety of tirzepatide in type 2 diabetes: the SURPASS-2 trial. New England Journal of Medicine. 2021.
4. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
5. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2): gastric emptying substudy. Diabetes Care. 2023.
6. Rubino DM et al. Effect of Weekly Subcutaneous Tirzepatide vs Placebo on Body Weight in Adults With Overweight or Obesity: The SURMOUNT-1 Randomized Clinical Trial, 104-week extension. Lancet Diabetes & Endocrinology. 2025.
7. Astrup A et al. Genetic predictors of GLP-1 receptor agonist response in obesity treatment. Obesity. 2024.
8. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
9. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021.
10. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
11. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. American Journal of Gastroenterology. 2022.
12. Heise T et al. Pharmacokinetic and pharmacodynamic properties of tirzepatide, a dual GIP and GLP-1 receptor agonist. Diabetes, Obesity and Metabolism. 2022.
13. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
14. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Ozempic, Wegovy, and Rybelsus are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other pharmaceutical manufacturer.